G. Jean, Effets métaboliques différentiels des sucres, Cah. Nutr. Diet. Hors, vol.2, issue.43, 2008.

G. Seematter, R. Chioléro, and L. Trappy, Métabolisme du glucose en situation physiologique. annales françaises d'anesthésie et de réanimation, 2009.
DOI : 10.1016/j.annfar.2009.02.031

B. Sanae, Les principaux transporteurs du glucose et de leur localisation, 2012.

T. Yamauchi, J. Kamon, Y. Minokoshi, Y. Ito, H. Waki et al., Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nature Medicine, vol.276, issue.11, pp.1288-95, 2002.
DOI : 10.1074/jbc.M005816200

URL : https://hal.archives-ouvertes.fr/hal-00174612

G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen et al., Role of AMP-activated protein kinase in mechanism of metformin action, Journal of Clinical Investigation, vol.108, issue.8, pp.1167-74, 2001.
DOI : 10.1172/JCI13505

W. Winder, Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle, Journal of Applied Physiology, vol.88, issue.3, pp.1017-1045, 2001.
DOI : 10.1152/ajpendo.2000.279.3.E622

A. Bouglé and D. Annane, Les effets de l'insuline: de la cellule à l'organisme entier. Annales françaises d'anesthésie et de réanimation, 2009.

P. Allain, Hormones d'origine digestive, Pharmacorama. [En ligne] CdM Editions, 2000.

D. Cani, C. Knauf, and R. Burcelin, Les hormones du tube digestif, Diabète&Obésité. Janvier, vol.2, p.5, 2007.

J. André, R. P. Scheen, P. Radermecker, B. J. Ernest, and . Jandrain, Inhibiteurs du cotransporteur du glucose SGLT2 rénal pour traiter le diabète de type 2, Rev Med Suisse, vol.7, pp.1621-1629, 2011.

J. Kuhn and L. Wolf, Hypoglycémies: aspects cliniques et stratégie

P. Galassetti, D. Tate, R. Neill, S. Morrey, D. Wasserman et al., Effect of Antecedent Hypoglycemia on Counterregulatory Responses to Subsequent Euglycemic Exercise in Type 1 Diabetes, Diabetes, vol.52, issue.7, pp.1761-1770, 2003.
DOI : 10.2337/diabetes.52.7.1761

P. Cryer, SYMPTOMS OF HYPOGLYCEMIA, THRESHOLDS FOR THEIR OCCURRENCE, AND HYPOGLYCEMIA UNAWARENESS, Endocrinology and Metabolism Clinics of North America, vol.28, issue.3, pp.495-500, 1999.
DOI : 10.1016/S0889-8529(05)70084-0

S. Davis, C. Shavers, R. Mosqueda-garcia, and F. Costa, Effects of Differing Antecedent Hypoglycemia on Subsequent Counterregulation in Normal Humans, Diabetes, vol.46, issue.8, pp.1328-1363, 1997.
DOI : 10.2337/diab.46.8.1328

M. Odièvre, Hypoglycémies du nourrisson et de l'enfant, Rev. Prat, vol.35, p.31, 1985.

. Ph, E. Passa, and . Abadie, Les hypoglycémies médicamenteuses, Rev. Prat, vol.35, p.31, 1985.

P. Lefebvre, . Lucky, and . Gerard, Le syndrome d'hypoglycémie réactionnelle, mythe ou réalité Journées annuelles de diabétologie de l'Hôtel- Dieu. Flammarion éd, pp.111-118, 1983.

A. Permutt, Postprandial Hypoglycemia, Diabetes, vol.25, issue.8, pp.719-733, 1976.
DOI : 10.2337/diab.25.8.719

A. Dufey, B. Köhler-ballan, and J. Philippe, Hypoglycémie non diabétique : diagnostic et prise en charge, Rev Med Suisse, vol.9, pp.1186-1191, 2013.

K. Allen and B. Frier, NOCTURNAL HYPOGLYCEMIA: CLINICAL MANIFESTATIONS AND THERAPEUTIC STRATEGIES TOWARD PREVENTION, Endocrine Practice, vol.9, issue.6, pp.530-573, 2003.
DOI : 10.4158/EP.9.6.530

D. Dunger and R. Hovorka, La fin du cauchemar : la prévention de l'hypoglycémie nocturne chez l'enfant. Diabetes Voice, 2007.

A. M. Farlane and . Philip, Le diabete et l'insuffisance rénale. La Fondation Canadienne du Rein, 2009.

C. Metaboliques, . Du, and . Diabète, Facultés de Médecine de Toulouse. [En ligne] [Citation : 14 07, 2014.

D. Clerc, O. Hugli, L. Trueb, and B. Yersin, Place de l'octréotide dans le traitement des hypoglycémies induites par les sulfonylurées, Rev Med Suisse, vol.4, pp.1764-1767, 2008.

P. Dougherty, S. Lee, D. Lung, and W. Klein-schwartz, Evaluation of the Use and Safety of Octreotide as Antidotal Therapy for Sulfonylurea Overdose in Children, Pediatric Emergency Care, vol.29, issue.3, pp.292-297
DOI : 10.1097/PEC.0b013e31828503cf

P. Boyle, K. Justice, and . Krentz, Octreotide reverse hyperinsulinemia and prevents hypoglycemia induced by sulfonylureas overdose, J Clin Endocrinol Metab, vol.76, pp.752-758, 1993.
DOI : 10.1210/jc.76.3.752

C. Blume-odom, A. Scalzo, and J. Weber, Euglycemia after Late Octreotide Use in Pediatric Glipizide Toxicity. North American Congress of Clinical Toxicology: abstr. 244 : s.n, 2010.

J. Neumiller, P. Odegard, and S. Haines, Weighing the potential benefits and risks of antidiabetic agents in older adults. Diabetes spectrum 25, pp.172-179, 2012.

P. Allain, Hypoglycémiants -Autres médicaments, Pharmacorama. [En ligne] CdM Editions, 2000.

J. Philippe, Rôle et place des analogues du GLP-1 dans le traitement du diabète de type 2. Revue Médicale Suisse, pp.8-10, 2009.

P. Allain, Les gliptines, sitagliptine et vildagliptine, antidiabétiques. Pharmacorama. [En ligne] [Citation : 08 10 2014

P. Allain, Inhibiteurs de l'enzyme de conversion de l'angiotensine. Pharmacorama. [En ligne] [Citation : 01 10, 2014.

P. Leung and P. Carlsson, Pancreatic Islet Renin Angiotensin System, Pancreas, vol.30, issue.4, pp.293-301, 2005.
DOI : 10.1097/01.mpa.0000158028.76666.76

M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher, Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator-Activated Receptor-?? Activity, Circulation, vol.109, issue.17, pp.2054-2061, 2004.
DOI : 10.1161/01.CIR.0000127955.36250.65

URL : http://circ.ahajournals.org/content/circulationaha/109/17/2054.full.pdf

Y. Miura, N. Yamamoto, S. Tsunekawa, S. Taqushi, Y. Equchi et al., Replacement of Valsartan and Candesartan by Telmisartan in Hypertensive Patients With Type 2 Diabetes: Metabolic and antiatherogenic consequences, Diabetes Care, vol.28, issue.3, pp.757-765, 2005.
DOI : 10.2337/diacare.28.3.757

G. Bertrand, R. Gross, P. Petit, M. Loubatières-marian, and G. Ribes, Evidences for a direct stimulatoy effect of cibenzoline on insulin secretion in rats, Eur J Pharmacol

M. Takahashi, H. Echizen, K. Takahashi, S. Shimada, and N. Aoyama, Extremely Prolonged Elimination of Cibenzoline at Toxic Plasma Concentrations in Patients With Renal Impairments, Therapeutic Drug Monitoring, vol.24, issue.4, pp.492-496, 2002.
DOI : 10.1097/00007691-200208000-00005

P. Lefort, M. Haissaquerre, J. Floro, P. Beauffigeau, J. Warin et al., Hypoglycemia caused by overdose of a new anti-arrhythmia agent: cibenzoline, Press Med, vol.17, issue.14, pp.687-91, 1988.

I. Strathman, E. N. Schubert, A. Cohen, and D. M. Nitzberg, Hypoglycemia in patient receving disopyramide phosphate. Drug Intelligence and Clinical Pharmacy, pp.635-638, 1985.
DOI : 10.1177/106002808301700905

I. J. Goldberg, C. K. Brown, and E. J. Rayfjeld, Disopyramide (Norpace??)-induced hypoglycemia, The American Journal of Medicine, vol.69, issue.3, pp.463-466, 1980.
DOI : 10.1016/0002-9343(80)90020-0

M. Rubin, G. Lakheim, and C. Pitchumonic, Disopyramide induced profound hypoglycemia, N.Y. State J Med, vol.83, pp.10527-10555, 1983.

T. Maurer, M. Winter, J. Koo, and T. Berger, Refractory hypoglycemia: a complication of topical salicylate therapy. Archives of Dermatology, pp.1455-1457, 1994.

K. Kelley and K. Helms, Drug-Induced Hypoglycemia

D. Durand and C. L. Jeunne, DOROSZ Guide pratique des médicaments

D. Costa and M. Huberman, Improvement of type 2 diabetes in a lung cancer patient treated with erlotinib. Diabetes Care, p.1711, 2006.

M. Haap, B. Gallwitz, C. Thamer, K. Müssig, H. Häring et al., Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor, Journal of Endocrinological Investigation, vol.24, issue.3, pp.688-692, 2007.
DOI : 10.1200/JCO.2006.06.5318

G. Dogu, M. Dikilitas, M. Ozkan, O. Karahan, Z. Karaca et al., Hypoglycemia in a patient with metastatic gastrointestinal stromal tumor: Is chemotherapy a reasonable option for symptom control? Uluslararasi Hematoloji-Onkoloji Dergisi, pp.48-51

. Voriconazole and . Vidal, [En ligne] [Citation : 27 10 2014

P. Allain, Antibiotiques agissant sur la paroi des mycobactéries - Antituberculeux. Pharmacorama. [En ligne] [Citation : 01 10, 2014.

A. Sarayaa, M. Yokokuraa, T. Gonoib, and S. Seinoa, Effects of fluoroquinolones on insulin secretion and beta-cell, Science Direct. European Journal of Pharmacology, vol.497, 2004.

M. Garber, . Seth, W. Pound, . Melanie, M. Miller et al., Hypoglycemia associated with the use of levofloxacin American journal of health-system pharmacy : AJHP : official journal of the, pp.1014-1023, 2009.

S. Basaria, M. Braga, and W. Moore, Doxycycline-Induced Hypoglycemia in a Nondiabetic Young Man, Southern Medical Journal, vol.95, issue.11, pp.1353-1354, 2002.
DOI : 10.1097/00007611-200295110-00026

. Allain, [Citation : 05 06 2014, 2000.

G. Cooper, The safety of fluoxetine-An update, J. Psychiatry, vol.153, issue.3, pp.77-86, 1988.

J. Wemicke, The side effect profile and safety of fluoxetine, J Clin Psychiatry, vol.46, issue.2, pp.59-67, 1985.

A. Mark, W. Deeg, and L. Edward, Hypoglycemia associated with the use of Fluoxetine, 1996.

P. Allain, Sérotoninomimétiques indirects. Pharmacorama. [En ligne] [Citation : 21 10, 2014.

. Amalyste, La gestion du risque médicamenteux grave. La revue Prescrire, p.343, 2012.

. A. Organisation-de-la-pharmacovigilance-nationale, En ligne] [Citation : 12 12 2013ansm.sante.fr/Declarer-un-effet- indesirable/Pharmacovigilance/Organisation-de-la-pharmacovigilance- nationale/%28offset%29/0. 73. insulines, 1998.

?. Pratique, Fiche pratique - Pharmaco-thérapeutique -Bêta-bloquants. [En ligne] 17 11 2011. [Citation : 20 02, 2015.